1187 The predictive value of core AG testing in the management of patients receiving PEG-IFN/ribavirin treatment — relevance for the early identification of non-responders and relapsers

MLA

Pascale Berthillon, et al. “1187 The Predictive Value of Core AG Testing in the Management of Patients Receiving PEG-IFN/Ribavirin Treatment — Relevance for the Early Identification of Non-Responders and Relapsers.” Hepatology, vol. 38, Jan. 2003, p. 729. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........bed9d4dc4fb493daaf76c0881e4e504c&authtype=sso&custid=ns315887.

APA

Pascale Berthillon, Pierre Pradat, Nicolas Voirin, Gaston Picchio, Johannes Wiegand, Juan Ignacio Esteban, Marianne Maynard, Hans L. Tillmann, M.P. Manns, & Maria Buti. (2003). 1187 The predictive value of core AG testing in the management of patients receiving PEG-IFN/ribavirin treatment — relevance for the early identification of non-responders and relapsers. Hepatology, 38, 729.

Chicago

Pascale Berthillon, Pierre Pradat, Nicolas Voirin, Gaston Picchio, Johannes Wiegand, Juan Ignacio Esteban, Marianne Maynard, Hans L. Tillmann, M.P. Manns, and Maria Buti. 2003. “1187 The Predictive Value of Core AG Testing in the Management of Patients Receiving PEG-IFN/Ribavirin Treatment — Relevance for the Early Identification of Non-Responders and Relapsers.” Hepatology 38 (January): 729. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........bed9d4dc4fb493daaf76c0881e4e504c&authtype=sso&custid=ns315887.